Thomas Schulze
Fondateur chez FundaMental Pharma GmbH
Postes actifs de Thomas Schulze
Sociétés | Poste | Début | Fin |
---|---|---|---|
FundaMental Pharma GmbH
FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | Directeur/Membre du Conseil | 18/11/2022 | - |
Fondateur | 01/01/2016 | - | |
Directeur Général | 01/01/2016 | 11/04/2024 |
Historique de carrière de Thomas Schulze
Anciens postes connus de Thomas Schulze
Sociétés | Poste | Début | Fin |
---|---|---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | President | 01/07/2003 | 19/04/2010 |
Bayer Yakuhin Ltd.
Bayer Yakuhin Ltd. Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The company is based in Osaka, Japan. | Corporate Officer/Principal | - | - |
BAYER AG | Corporate Officer/Principal | - | - |
november AG
november AG Financial ConglomeratesFinance November AG is a holding company, which engages in the founding, acquisition, development, and management of companies. Its activities focus on the fields of medical, environmental, and biotechnology. It also supports the business development of its subsidiary companies and investments. The company was founded on November 26, 1996 and is headquartered in Cologne, Germany. | Directeur des opérations | - | - |
Formation de Thomas Schulze
Freie Universität Berlin | Doctorate Degree |
Statistiques
Internationale
Allemagne | 6 |
Japon | 2 |
Opérationnelle
Corporate Officer/Principal | 2 |
President | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 5 |
Finance | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
BAYER AG | Health Technology |
Entreprise privées | 4 |
---|---|
november AG
november AG Financial ConglomeratesFinance November AG is a holding company, which engages in the founding, acquisition, development, and management of companies. Its activities focus on the fields of medical, environmental, and biotechnology. It also supports the business development of its subsidiary companies and investments. The company was founded on November 26, 1996 and is headquartered in Cologne, Germany. | Finance |
Bayer Yakuhin Ltd.
Bayer Yakuhin Ltd. Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Bayer Yakuhin Ltd. is a Japanese company that manufactures pharmaceuticals and diagnostic substances. The company is based in Osaka, Japan. | Health Technology |
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
FundaMental Pharma GmbH
FundaMental Pharma GmbH Pharmaceuticals: MajorHealth Technology FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016. | Health Technology |
- Bourse
- Insiders
- Thomas Schulze
- Expérience